They also essentially neutralize the effect of ARMS2/HTRA1 risk polymorphisms, which indicates that protective complement-directed therapies designed to prevent AMD driven by CFH-CFHR5 risk haplotypes may also be effective when AMD is driven by ARMS2/HTRA1 risk variants. Here, CFH is linked to age-related macular degeneration.